Recon: FDA rejects ivonescimab for lung cancer indication; J&J to buy eye disease biotech Ollin Biosciences for up to $3.3B
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
comments(0)
5-min edit window · permanent after that